Page 4 - Immune Effector Cell Therapy Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immune effector cell therapy program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immune Effector Cell Therapy Program Today - Breaking & Trending Today

Exacis Biotherapeutics Announces Key Additions To Company's Scientific Advisory Board

Exacis Biotherapeutics Announces Key Additions To Company's Scientific Advisory Board
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Caron Jacobson , Pamela Munster , Gregory Fiore , Evren Alici , Exacis Biotherapeutics , Effector Cell Therapy Program , Karolinska Institute , University Of Calfornia San Francisco , Professor Of Medicine At Harvard Medical School , Vycellix Inc , Molecular Oncology Program , Department Of Medicine Hematology Oncology , Gene Therapy Group , Exacis Biotherapeutics Inc , Dana Farber Cancer Institute , Helen Diller Family Comprehensive Cancer Center , Scientific Advisory Board , Calfornia San Francisco , Early Phase Clinical Trials Unit , Diller Family Comprehensive Cancer , Assistant Professor , Harvard Medical School , Medical Director , Immune Effector Cell Therapy Program , Dana Farber Cancer ,

Longer-term Data for Kite's Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis

94% of Patients Achieved a Response at 18 Months in Pivotal ZUMA-5 Trial Yescarta Reduced Risk of Death by 58% Compared to Current Therapies in Weighted Analysis of ZUMA-5 Compared to SCHOLAR-5 External Control Cohort Late-breaking Data Presented at European Hematology Association 2021 Kite, a Gilead Company today announced follow-up results from the pivotal ZUMA-5 trial of Yescarta ® the first and . ....

United Kingdom , Santa Monica , United States , Foster City , City Of , Mary Lynn Carver , Jacquie Ross , John Gribben , Carona Jacobson , Data Presented At European Hematology Association , Effector Cell Therapy Program , Gilead Sciences , Drug Administration , Harvard Medical School , Gilead Sciences Inc , Exchange Commission , Cancer Research United Kingdom Barts Centre , Gilead Company , Meeting Of The European Hematology Association , Gilead Public Affairs , Gilead Company Nasdaq , Dana Farber Cancer Institute , Patients Achieved , Yescarta Reduced Risk , Current Therapies , Weighted Analysis ,

U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

United States , Santa Monica , Foster City , Christi Shaw , Jacquie Ross , Carona Jacobson , Lee Greenberger , Nathan Kaiser , Effector Cell Therapy Program , Gilead Sciences , Leukemia Lymphoma Society , Drug Administration , Harvard Medical School , Gilead Sciences Inc , Exchange Commission , Gilead Company , Gilead Public Affairs , Gilead Company Nasdaq , Dana Farber Cancer Institute , Cell Therapy Approved , Indolent Follicular Lymphoma , Approval Marks , Third Indication , Kite Cell Therapy , Patients Responded , Median Duration ,

U.S. FDA Approves Yescarta for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

Posted on
17160
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta
® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The approval makes Yescarta the first chimeric antigen receptor (CAR) T-cell therapy approved for patients with indolent follicular lymphoma, follows FDA Breakthrough Therapy Designation and a priority review, and marks the third approved indication for a Kite cell therapy.
The approval is based on results from ZUMA-5, a single-arm, open-label study in which 91 percent of patients with relapsed or refractory FL (n=81) responded to Yescarta, including an estimated 74 percent of patients in a continued remission at 18 months (Kaplan-Meier estimate). Among all FL patients, median durat ....

United States , Santa Monica , Foster City , Christi Shaw , Jacquie Ross , Carona Jacobson , Lee Greenberger , Nathan Kaiser , Effector Cell Therapy Program , Gilead Sciences , Leukemia Lymphoma Society , Drug Administration , Harvard Medical School , Gilead Sciences Inc , Exchange Commission , Gilead Company , Gilead Public Affairs , Gilead Company Nasdaq , Dana Farber Cancer Institute , Therapy Designation , Medical Director , Immune Effector Cell Therapy Program , Assistant Professor , Harvard Medical , Chief Executive Officer , Chief Scientific Officer ,